Home » Posts tagged with » cancer
CStone Pharmaceuticals strikes $480m worth oncology deal with Pfizer

CStone Pharmaceuticals strikes $480m worth oncology deal with Pfizer

US pharma giant Pfizer has entered into a collaboration deal worth up to $480 million with Chinese biopharma company CStone Pharmaceuticals to address the oncological needs in China. CStone Pharmaceuticals is engaged in developing and commercializing immuno-oncology and precision medicines for cancer patients. The collaboration will be formed between the Chinese firm and Pfizer’s subsidiaries […]

Galecto raises $64m to develop fibrosis and cancer treatments

Galecto, a Danish biotech company, has raised $64 million in an equity financing round, for developing novel treatments for fibrosis and cancer. Led by Soleus Capital and co-led by Eir Ventures, the funding round is said to strengthen the existing cash balance of Galecto, extending its cash runway into late 2022. The financing round saw […]

Continue reading …
Illumina to take full ownership of cancer screening company GRAIL in $8bn deal

Illumina acquisition of GRAIL : US sequencing company Illumina has agreed to fully acquire California-based cancer screening company GRAIL in a cash and stock deal worth $8 billion. It was Illumina which had established GRAIL in 2016. Subsequently, it was separated as an independent company driven by Illumina’s NGS technology for developing data science and […]

Continue reading …
Galera Therapeutics enrolls patients for pancreatic cancer trial of GC4419

Galera Therapeutics said that it has wrapped up enrollment of patients for its phase 1b/2a safety and anti-cancer efficacy clinical trial of the combination of avasopasem manganese (GC4419) with stereotactic body radiation therapy (SBRT) in patients having locally advanced pancreatic cancer (LAPC). The US biotech company said that its investigational, selective small molecule superoxide dismutase (SOD) […]

Continue reading …
ABM Therapeutics begins phase 1 trial of BRAF inhibitor ABM-1310

ABM Therapeutics said that the first cancer patient has been enrolled and dosed with its lead candidate ABM-1310, a BRAF inhibitor, in a phase 1 clinical trial in the US. According to the clinical-stage biopharma company, the BRAF inhibitor had shown superior properties in pre-clinical animal models. The brain-penetrant small molecule is expected to be […]

Continue reading …
Ascentage, Acerta to evaluate APG-2575, CALQUENCE combo in r/r CLL/SLL

Ascentage Pharma has entered into a clinical collaboration with Acerta Pharma, the hematology research and development center of excellence of AstraZeneca to assess the combination of Bcl-2 and Bruton’s Tyrosine Kinase (BTK) inhibitors in a type of lymphoma. As per the collaboration terms, Ascentage Pharma will sponsor a clinical trial to evaluate the efficacy and […]

Continue reading …
Leap Therapeutics gets FDA orphan status for DKN-01 for gastric and gastroesophageal junction cancer

US immuno-oncology company Leap Therapeutics has been granted orphan drug designation for DKN-01 from the US Food and Drug Administration (FDA) for the treatment of gastric and gastroesophageal junction cancer. DKN-01, which is a humanized monoclonal antibody, has been designed to bind to and block the activity of the Dickkopf-1 (DKK1) protein, a modulator of […]

Continue reading …
Takeda gets extended EC approval for ADCETRIS in sALCL

Takeda Pharmaceutical has secured extended approval for ADCETRIS (brentuximab vedotin) in the European Union to include the treatment of previously untreated systemic anaplastic large cell lymphoma (sALCL) in adult patients. The approval from the European Commission (EC) is for the combination of ADCETRIS with CHP (cyclophosphamide, doxorubicin, prednisone. It comes in the wake of a […]

Continue reading …
PADCEV, KEYTRUDA combination for advanced bladder cancer gets FDA breakthrough therapy status

PADCEV, KEYTRUDA combination : Astellas Pharma and Seattle Genetics said that the combination of PADCEV (enfortumab vedotin-ejfv) and Merck’s anti-PD-1 therapy KEYTRUDA (pembrolizumab) has been given breakthrough therapy designation from the US Food and Drug Administration (FDA) in first-line advanced bladder cancer. The FDA breakthrough therapy status for PADCEV, KEYTRUDA combination is for the treatment […]

Continue reading …
Pinpoint Therapeutics secures funds for developing autophagy inhibitors for cancer

Pinpoint Therapeutics, a US biopharma company focused on developing autophagy inhibitors for cancer treatment, has secured $1 million in debt financing led by California-based venture capital firm Kairos Ventures. The preclinical stage company was founded in 2018 through PCI Ventures, a division of the Penn Center for Innovation (PCI) at the University of Pennsylvania. It […]

Continue reading …
Page 1 of 8123Next ›Last »